JP2005516967A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516967A5
JP2005516967A5 JP2003559508A JP2003559508A JP2005516967A5 JP 2005516967 A5 JP2005516967 A5 JP 2005516967A5 JP 2003559508 A JP2003559508 A JP 2003559508A JP 2003559508 A JP2003559508 A JP 2003559508A JP 2005516967 A5 JP2005516967 A5 JP 2005516967A5
Authority
JP
Japan
Prior art keywords
secretase inhibitor
inhibitor according
manufacture
amyloid
secretase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003559508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516967A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/000504 external-priority patent/WO2003059346A1/en
Publication of JP2005516967A publication Critical patent/JP2005516967A/ja
Publication of JP2005516967A5 publication Critical patent/JP2005516967A5/ja
Withdrawn legal-status Critical Current

Links

JP2003559508A 2002-01-18 2003-01-20 β−セクレターゼインヒビター Withdrawn JP2005516967A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02001339 2002-01-18
EP02012566 2002-06-05
PCT/EP2003/000504 WO2003059346A1 (en) 2002-01-18 2003-01-20 Beta-secretase inhibitors

Publications (2)

Publication Number Publication Date
JP2005516967A JP2005516967A (ja) 2005-06-09
JP2005516967A5 true JP2005516967A5 (enExample) 2006-01-05

Family

ID=26077568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003559508A Withdrawn JP2005516967A (ja) 2002-01-18 2003-01-20 β−セクレターゼインヒビター

Country Status (6)

Country Link
US (1) US20050239899A1 (enExample)
EP (1) EP1467729A1 (enExample)
JP (1) JP2005516967A (enExample)
AU (1) AU2003205630A1 (enExample)
CA (1) CA2473441A1 (enExample)
WO (1) WO2003059346A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20060281803A1 (en) * 2003-09-23 2006-12-14 Lindsley Craig W Pyrazole modulators of metabotropic glutamate receptors
US7847100B2 (en) * 2004-04-20 2010-12-07 Merck, Sharp & Dohme, Inc. 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease
EP1791818A1 (en) * 2004-09-14 2007-06-06 The Genetics Company, Inc. Hydrazone derivatives and their use as beta secretase inhibitors
ATE531367T1 (de) * 2004-09-17 2011-11-15 Whitehead Biomedical Inst Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung
CN101351460A (zh) 2005-10-31 2009-01-21 先灵公司 天冬氨酰蛋白酶抑制剂
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
EA201000675A1 (ru) * 2007-12-18 2011-06-30 Гленмарк Фармасьютикалс, С.А. Производные хромана как модуляторы trpv3
CA2728405A1 (en) * 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Chromane derivatives as trpv3 modulators
CN104311472B9 (zh) 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
PL2342205T4 (pl) * 2008-08-27 2016-12-30 Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚o-甲基轉移酶活性抑制化合物
AP2015008858A0 (en) 2013-05-28 2015-11-30 Astrazeneca Ab Chemical compounds
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
CN109362222B (zh) 2016-02-05 2021-03-19 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
IL264955B (en) 2016-09-02 2022-06-01 Ironwood Pharmaceuticals Inc Fused bicyclic sgc stimulators
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN109745324B (zh) * 2017-11-06 2026-02-06 中国科学院上海营养与健康研究所 非经典NF-kB通路的小分子抑制剂及其应用
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法
EP3847158B1 (en) 2018-09-06 2026-06-24 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07309822A (ja) * 1994-05-18 1995-11-28 Asahi Chem Ind Co Ltd フェニルプロピオンアニリド誘導体
WO1998003475A1 (en) * 1996-07-24 1998-01-29 Novartis Ag Pesticidal compositions
US6660737B2 (en) * 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones

Similar Documents

Publication Publication Date Title
ES2613931T3 (es) Compuestos peptídicos para tratar el estado epiléptico refractario
TWI354666B (en) Heterocyclic aspartyl protease inhibitors
RU2309953C2 (ru) Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
TW200607807A (en) Macrocyclic beta-secretase inhibitors
JP2006507220A5 (enExample)
JP2006512417A5 (enExample)
WO2012072713A2 (en) Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
RU2005103398A (ru) Производные 7,8,9,10-тетрагидро-6h-азепино-, 6,7,8,9-тетрагидропиридо-и 2,3-дигидро-2h-пирроло-[2,1-b]-хиназолинона
JP2007511504A5 (enExample)
JP2007508360A5 (enExample)
JP2006503850A5 (enExample)
JP2009515887A5 (enExample)
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
JP2004137288A5 (enExample)
JP2003509349A5 (enExample)
JP2006500394A5 (enExample)
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
WO2005056524A3 (en) Therapeutic agents useful for treating pain
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
JP2005516967A (ja) β−セクレターゼインヒビター
JP2015535247A5 (enExample)
JP2006504738A5 (enExample)
JP2004509845A5 (enExample)
JP2004534064A5 (enExample)
EA200501425A1 (ru) Арилвинилазациклоалкановые соединения и способы их получения и применения